---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261798"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:56:39.873127+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TERN-701 Phase 1 CARDINAL trial shows 75% cumulative MMR rate by 24 weeks in refractory CML; abstract at ASH

## Summary
- 75% (24/32) overall cumulative MMR rate by 24 weeks; 64% (14/22) achieved MMR, 100% (10/10) maintained MMR, no MMR loss.
- In difficult subgroups: 69% MMR in patients with lack of efficacy to last TKI, 60% with prior asciminib, 67% with prior asciminib/ponatinib/investigational TKI.
- Safety: 87% (48/55) remain on treatment; no DLTs; Grade 3+ TEAEs <10% (neutropenia 7%, thrombocytopenia 4%).
- Patients heavily pretreated: median 3 prior TKIs, 64% discontinued last TKI due to lack of efficacy, 36% had prior asciminib.

## SEC filing metadata
- accession: 0001193125-25-261798
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312525261798/0001193125-25-261798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312525261798/d78407d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261798
- JSON: https://secwatch.observer/filing/0001193125-25-261798.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.